Latest news with #esophagealCancer
Japan Times
6 days ago
- Health
- Japan Times
Team develops esophageal cancer prediction method using the inside of the cheek
A team of Kyoto University and other researchers has developed a method of predicting with high accuracy the risk of someone developing esophageal cancer by analyzing cells collected from inside the person's cheeks. If brought into practical use, the method could facilitate early cancer detection and cancer prevention through lifestyle improvements. The team's findings were published in an online international medical journal in April. Its study covered 222 people age 40-94, all with a history of smoking and drinking who either had esophageal cancer or did not. The team swabbed the inside of their cheeks to extract cheek mucosa cells and analyzed any genetic mutations. Participants with a lower tolerance for alcohol had more genetic mutations in their extracted cells when their alcoholic intake increased. On the other hand, those whose bodies were capable of processing alcohol well did not display such an increase. The team also found that esophageal cancer patients had more genetic mutations than those who did not, even if their cancer was discovered at an early stage. The team managed to make cancer probability predictions with an accuracy of over 70% by analyzing various genetic mutation data together. The team found "what is believed to be a biomarker that indicates (cancer) risks more objectively and accurately than with the conventional method of interviewing (patients) on their lifestyle habits and predispositions," said team member Akira Yokoyama, lecturer at Kyoto University Hospital.
Yahoo
23-05-2025
- Business
- Yahoo
Trends Shaping the Barrett's Esophagus (BE) Industry, 2025-2030: Technological Advances in Diagnostics Elevate BE Surveillance
Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Barrett's Esophagus - Global Strategic Business Report" has been added to global market for Barrett's Esophagus was valued at US$4.9 Billion in 2024 and is projected to reach US$6.1 Billion by 2030, growing at a CAGR of 3.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Barrett's Esophagus growth in the Barrett's Esophagus market is underpinned by a confluence of epidemiological, technological, and policy drivers. Increasing GERD burden, combined with greater public and physician awareness of BE-cancer progression risks, is elevating demand for routine screening and early intervention. Health systems are recognizing the cost-effectiveness of preventing esophageal cancer through proactive BE management, prompting wider adoption of minimally invasive diagnostics and ablation endorsements of new imaging and therapeutic tools, coupled with industry efforts to bundle diagnostic and treatment platforms, are streamlining the care pathway. Cross-disciplinary collaboration and data-sharing via registries are enhancing outcome transparency and evidence-based decision-making. As healthcare moves toward precision medicine and value-based care, a critical question emerges: Can the BE market continue to integrate early detection with personalized intervention strategies to deliver scalable, cost-effective cancer prevention across global care settings?Report ScopeThe report analyzes the Barrett's Esophagus market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined Drug Class (Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Insights: Market Growth: Understand the significant growth trajectory of the Proton Pump Inhibitors segment, which is expected to reach US$2.4 Billion by 2030 with a CAGR of a 2.9%. The H2 Receptor Antagonists segment is also set to grow at 4.7% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.3 Billion in 2024, and China, forecasted to grow at an impressive 6.9% CAGR to reach $1.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Key Questions Answered: How is the Global Barrett's Esophagus Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as AbbVie Inc., Abbott Laboratories, Addex Therapeutics Ltd., Aurobindo Pharma Ltd., Bayer AG and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Some of the 34 companies featured in this Barrett's Esophagus market report include: AbbVie Inc. Abbott Laboratories Addex Therapeutics Ltd. Aurobindo Pharma Ltd. Bayer AG Boehringer Ingelheim GmbH Boston Scientific Corporation Castle Biosciences Cipla Inc. Cook Medical Inc. Dr. Reddy's Laboratories Ltd. Eisai Co., Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc Johnson & Johnson Lupin Limited Medtronic plc Merck & Co., Inc. Novartis AG Tariff Impact Analysis: Key Insights for 2025Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes Report Attribute Details No. of Pages 274 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $4.9 Billion Forecasted Market Value (USD) by 2030 $6.1 Billion Compound Annual Growth Rate 3.9% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Barrett's Esophagus Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising GERD Prevalence Drives Demand for Early Screening and Diagnosis of Barrett's Esophagus Advancements in Endoscopic Imaging and Biopsy Tools Improve Detection Accuracy High-Risk Patient Monitoring Through Surveillance Programs Fuels Use of Specialized Devices Minimally Invasive Treatment Modalities Like RFA and Cryotherapy Expand Therapeutic Reach Clinical Guidelines Emphasize Early Intervention to Prevent Progression to Esophageal Adenocarcinoma Biomarker Research Enhances Risk Stratification and Personalized Surveillance Protocols Growing Awareness of Barrett's Risk Factors Spurs Referrals From Primary Care to GI Specialists EHR Integration and Registry Participation Improve Patient Tracking and Longitudinal Outcomes AI-Based Image Analysis Tools Support Enhanced Detection in Diagnostic Endoscopy Device Manufacturers Focus on Comfort, Precision, and Workflow Efficiency in Diagnostic Kits Health System Adoption of Barrett's Pathways Improves Standardization of Care Delivery Expansion of Digestive Health Programs in Hospitals Elevates Focus on Esophageal Precancers For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
21-05-2025
- Politics
- Washington Post
Tributes pour in to Gerry Connolly, ‘the epitome of a public servant'
Friends and colleagues mourned Rep. Gerry Connolly (D-Virginia) on Wednesday, remembering the 75-year-old Democrat as a steward of civic improvements in Fairfax County and a fiery champion of federal workers. Connolly announced his diagnosis of esophageal cancer last fall shortly after winning a ninth term, but the aggressive return of the illness following treatment forced him to make it his final term. He also stepped down from his role as the top Democrat on the House Oversight Committee, and Democrats will decide internally who will fill his slot on that committee.
E&E News
21-05-2025
- Politics
- E&E News
Northern Virginia Rep. Gerry Connolly dies at 75
Gerry Connolly, a longtime Democratic member of Congress from Northern Virginia known for his advocacy of the federal workforce, died Wednesday. He was 75 years old. The longtime lawmaker's death was announced by his family via a statement from his congressional office. 'We were fortunate to share Gerry with Northern Virginia for nearly 40 years because that was his joy, his purpose, and his passion,' the family said in its statement. 'His absence will leave a hole in our hearts, but we are proud that his life's work will endure for future generations.' Advertisement On April 28, Connolly said he would not seek reelection in 2026 and also said he would step down from his role as the ranking member of the House Committee on Oversight and Government Reform, saying his esophageal cancer had returned.
New York Times
21-05-2025
- Politics
- New York Times
Gerald Connolly, 75, Top Democrat on House Oversight Committee, Is Dead
Representative Gerald E. Connolly of Virginia, a feisty Democrat who prided himself on getting things done, and who defeated Representative Alexandria Ocasio-Cortez of New York to become his party's top member of the powerful House Oversight Committee, died on Wednesday at his home in Fairfax County, Va. He was 75. His family announced the death. Mr. Connolly said late last year that he had esophageal cancer and would fight the disease. But in April, he told his constituents that the treatments had been unsuccessful and that he would not seek re-election in 2026. A nine-term congressman from the affluent suburbs of Northern Virginia, Mr. Connolly vigorously defended the interests of the legions of government workers who live in his district, whether by extending the Washington Metro to their communities or by battling President Trump's efforts to weaken civil service job protections for the federal work force. Mr. Connolly fought an executive order issued by Mr. Trump in 2020, near the end of the president's first term, to strip job protections from tens of thousands of career civil servants by reclassifying them as so-called Schedule F political appointees who could be fired at will. The order was reversed by President Joseph R. Biden Jr. This year, as Mr. Trump launched his second term in office with shock-and-awe orders aimed at purging what he viewed as 'deep state' resistance to his policies, Mr. Connolly spoke out. 'Trump is on a wrecking cruise to de-professionalize the civil service and threaten basic services to Americans,' he told The New York Times in January. 'It's unlawful firings and impoundments that threaten to unravel 142 years' of the tradition of a 'civil service immune from partisan politics.' Mr. Connolly was first elected to the House in 2008. His victory, in an open race to replace a retiring Republican, was part of a blue wave that year that heralded Virginia's political realignment from a reliably red state to one that leans blue in federal elections. An influx of immigrants and of high-tech jobs to Mr. Connolly's district changed its demographics and its politics. He moved with those changes, evolving from a nuts-and-bolts proponent of infrastructure to a fiery critic of what he saw as ideological overreach by both Trump administrations. As an increasingly visible member of the House Oversight and Accountability Committee, which lawmakers of both parties use to stymie presidents of the opposing party, Mr. Connolly led an ultimately successful effort to block the Trump White House from adding a citizenship question to the 2020 census. The Oversight Committee in 2019 sued Attorney General William P. Barr and Commerce Secretary Wilbur Ross for refusing to turn over documents about a citizenship question, which critics said was politically motivated to intimidate immigrants from census participation and to shrink the number of Democratic seats. In December, Mr. Connolly vied with Ms. Ocasio-Cortez, a rising star of the left, in a generational contest for the top Democratic position on the Oversight Committee. Mr. Connolly's bid was boosted by the endorsement and the active lobbying of Nancy Pelosi, the former speaker of the House. House Democrats chose him in a secret ballot. The often pugnacious Mr. Connolly criticized a Republican bill in 2024 to rename Dulles International Airport, some of whose employees live in his district, after Mr. Trump. 'If Republicans want to name something after him,' he told The Guardian, 'I'd suggest they find a federal prison.' Gerald Edward Connolly, who was known as Gerry, was born on March 30, 1950, in Boston. He was one three children of Edward Connolly, an insurance salesman, and Mary Therese (O'Kane) Connolly, a registered nurse. He received a B.A. in literature from Maryknoll College in Glen Ellyn, Ill., and an M.A. in public administration from Harvard University in 1979. His survivors include his wife, Cathy Smith, and their daughter, Caitlin. For a decade, from 1979 to 1989, Mr. Connolly worked as a staff member of the Senate Committee on Foreign Relations. Years later, as a member of Congress, he held a seat on the House Committee on Foreign Affairs. Before serving in Congress for 16 years, Mr. Connolly was on the Fairfax County Board of Supervisors for 14 years, beginning in 1995. He was elected chairman in 2003. He promoted the transformation of the county hub at Tysons Corner from a sprawl of shopping malls into a major office center. As a supervisor, he dreamed of extending the Washington Metro deep into the Virginia suburbs. When he reached Congress, he helped procure funding for the Silver Line, which was built out to Tysons Corner in 2014. 'I know this is going to sound corny,' he told The Washington Post that year, 'but I look out at that now, and my heart soars.'
